Castle Biosciences/$CSTL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Castle Biosciences
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Ticker
$CSTL
Sector
Primary listing
Employees
798
Headquarters
Website
CSTL Metrics
BasicAdvanced
$631M
-
-$0.33
1.09
-
Price and volume
Market cap
$631M
Beta
1.09
52-week high
$33.33
52-week low
$14.59
Average daily volume
622K
Financial strength
Current ratio
6.851
Quick ratio
6.47
Long term debt to equity
7.431
Total debt to equity
8.202
Interest coverage (TTM)
-69.64%
Profitability
EBITDA (TTM)
19.437
Gross margin (TTM)
81.00%
Net profit margin (TTM)
-2.73%
Operating margin (TTM)
-6.66%
Effective tax rate (TTM)
7.62%
Revenue per employee (TTM)
$430,000
Management effectiveness
Return on assets (TTM)
-2.79%
Return on equity (TTM)
-2.15%
Valuation
Price to revenue (TTM)
1.782
Price to book
1.38
Price to tangible book (TTM)
1.79
Price to free cash flow (TTM)
17.868
Free cash flow yield (TTM)
5.60%
Free cash flow per share (TTM)
1.217
Growth
Revenue change (TTM)
20.40%
Earnings per share change (TTM)
193.35%
3-year revenue growth (CAGR)
46.47%
3-year earnings per share growth (CAGR)
-42.38%
What the Analysts think about CSTL
Analyst ratings (Buy, Hold, Sell) for Castle Biosciences stock.
Bulls say / Bears say
DecisionDx-Melanoma test volume grew to 9,981 reports in Q2 2025, up 4% year-over-year, and received FDA Breakthrough Device designation, underscoring regulatory recognition of its clinical innovation (Nasdaq).
TissueCypher test report volume increased 117% year-over-year in Q1 2025, driven by expanded sales force coverage and rising clinical demand in the gastrointestinal segment (Nasdaq).
Castle completed the acquisition of Previse in Q2 2025, adding methylation-based and non-endoscopic diagnostic technologies to broaden its gastroenterology portfolio (Nasdaq).
Medicare stopped covering the DecisionDx-SCC test effective April 24, 2025 due to a Novitas LCD listing it as noncovered, removing a significant revenue source (Nasdaq).
The company discontinued its IDgenetix pharmacogenomics test in May 2025 amid reimbursement challenges, resulting in a sharp decline in that product’s revenues (Nasdaq).
Castle’s gross margin fell to 77.3% in Q2 2025 from 80.7% in Q2 2024, and net income nearly halved to $4.5 million, reflecting margin compression and increased operating expenses (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
CSTL Financial Performance
Revenues and expenses
CSTL Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Castle Biosciences stock?
Castle Biosciences (CSTL) has a market cap of $631M as of September 18, 2025.
What is the P/E ratio for Castle Biosciences stock?
The price to earnings (P/E) ratio for Castle Biosciences (CSTL) stock is 0 as of September 18, 2025.
Does Castle Biosciences stock pay dividends?
No, Castle Biosciences (CSTL) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Castle Biosciences dividend payment date?
Castle Biosciences (CSTL) stock does not pay dividends to its shareholders.
What is the beta indicator for Castle Biosciences?
Castle Biosciences (CSTL) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.